Studies recruiting newly diagnosed patients exploit molecular markers to some extent, especially to distinguish WNT-activated MBs utilizing mandatory testing for CTNNB1 mutational status or IHC positivity. The gene discussed is CTNNB1; the disease is Mobius syndrome.